Metabolic & Cardiometabolic
ezetimibe decreases cardiovascular disease
Part of: 💊 statins, 💊 ezetimibe
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
Ezetimibe added to a statin reduces major cardiovascular events post-ACS (IMPROVE-IT) - modest absolute effect (HR 0.94, ~2% over 7y, NNT ~50), proportional to the extra LDL reduction (consistent with 'lower LDL by any mechanism'). No mortality benefit.
The evidence (9)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Cannon CP, et al. (IMPROVE-IT) 2015 · N Engl J Med | RCT | supports | high | [FT-verified] IMPROVE-IT NEJM paywalled; ARR 2.0%/7y (LDL 53.7 vs 69.5); landmark holds |
| Mahmoud 2025 2025 · Proc Bayl Univ Med Cent | meta-analysis | mixed | moderate | [FT-verified] FT 47-RCT: beats double-dose statin on LDL but NO diff in MI/mortality/stroke + more severe AEs; lipid-surrogate not events |
| Zhao X et al 2026 · study_type: meta-analysis | meta-analysis | supports | high | Network meta-analysis (18 RCTs, 89,717 diabetic participants): statins, ezetimibe, PCSK9i, and bempedoic acid each reduced MACE risk vs comparators; ezetimibe (and evolocumab) specifically associated with reduced MI risk. |
| He H et al 2026 · study_type: observational | observational | supports | moderate | Propensity-matched cohort (n=1,452 combo vs 5,808 high-intensity statin monotherapy): moderate-intensity statin+ezetimibe associated with significantly lower risk of incident PCI/CABG (HR 0.57, 95% CI 0.36-0.91) plus greater LDL-C reduction |
| Kataoka Y et al 2026 · study_type: observational | observational | supports | moderate | Retrospective cohort of 780 CAD patients achieving LDL-C <1.4 mmol/L post-PCI: those who developed MACE were less likely to be on ezetimibe (45.8% vs 63.2%, p=0.023) than those without MACE. |
| Liu HH et al 2026 · study_type: observational | observational | supports | moderate | Narrative review of ezetimibe evidence in ASCVD: monotherapy lowers LDL-C ~17-26% and reduces MACE vs placebo; adding ezetimibe to statin achieves greater LDL-C reduction, reduces plaque burden, and lowers CV event incidence vs statin alone |
| Oyama 2021 2021 · J Am Coll Cardiol | RCT | supports | high | IMPROVE-IT: ezetimibe+statin CV benefit consistent across baseline LDL strata |
| Sajid EU et al 2026 · study_type: meta-analysis | meta-analysis | mixed | low | Systematic review/meta-analysis (9 studies, 179,621 patients post-PCI): moderate-intensity statin+ezetimibe vs high-intensity statin monotherapy showed no significant MACE difference (RR 0.96, 95% CI 0.81-1.12), though modest reductions in |
| Vuorio A et al 2026 · study_type: observational | observational | supports | low | Commentary discussing the EWTOPIA 75 trial, which found ezetimibe monotherapy (without statin) reduced ASCVD events in adults ≥75y without prior CAD; proposes mechanistic explanations (age-related rise in cholesterol absorption). |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.